-
Eidos Therapeutics Inc. (EIDX $122.21)
- $122.21 Cap: $4.72B
- View EIDX Profile
- View Questions on EIDX
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
BMO Laddered Preferred Share Index ETF (ZPR $11.80)
- $11.80 P/E (TTM): 11.07X Cap: $1.76B
- View ZPR Profile
- View Questions on ZPR
-
Global X Active Preferred Share ETF (HPR $9.99)
- $9.99 P/E (TTM): 8.39X Cap: $1.23B
- View HPR Profile
- View Questions on HPR
-
iShares Global Real Estate Index ETF (CGR $30.56)
- $30.56 P/E (TTM): 71.7X Cap: $208M
- View CGR Profile
- View Questions on CGR
-
Vanguard Real Estate Index Fund ETF (VNQ $90.38)
- $90.38 P/E (TTM): 34.56X Cap: $33.48B
- View VNQ Profile
- View Questions on VNQ
-
iShares MSCI Mexico ETF (EWW $59.24)
- $59.24 P/E (TTM): 6.24X Cap: $1.75B
- View EWW Profile
- View Questions on EWW
-
Invesco Preferred ETF (PGX $11.16)
- $11.16 P/E (TTM): 15.82X Cap: $3.94B
- View PGX Profile
- View Questions on PGX
-
iShares U.S. Preferred Stock (PFF $31.14)
- $31.14 P/E (TTM): 18.67X Cap: $14.22B
- View PFF Profile
- View Questions on PFF
-
RBC Canadian Preferred Share ETF (RPF $23.48)
- $23.48 P/E (TTM): 15.02X Cap: $636M
- View RPF Profile
- View Questions on RPF
-
Eidos Therapeutics Inc. (EIDX $122.21)
- $122.21 Cap: $4.72B
- View EIDX Profile
- View Questions on EIDX
-
iShares MSCI Brazil ETF (EWZ $27.10)
- $27.10 Cap: $4.99B
- View EWZ Profile
- View Questions on EWZ
-
iShares MSCI Spain ETF (EWP $44.31)
- $44.31 P/E (TTM): 42.63X Cap: $1.31B
- View EWP Profile
- View Questions on EWP
Q: Hello, looking for emerging markets, ETFs you recommend ex China and ex India (as I already hold INDY and FXI). Also looking for non-Canadian REIT ETF recommendations (I hold XRE). Finally what are your thoughts on preferred share ETFs and which would you recommend (Canadian or not) outside of CPD.
Thanks!
Thanks!
-
Eidos Therapeutics Inc. (EIDX $122.21)
- $122.21 Cap: $4.72B
- View EIDX Profile
- View Questions on EIDX
Q: Hi 5i team,
Thank you for your answer on Eidos Therapeutic on 21st, June. I own this stock and has gone up 30% + thanks to your positive comment ( at least the ceo has bought 28m in shares), I usually hold on to my winner and let it runs, but I do not understand why it gone up so fast within a short period of time with no news.
As stated in your answer, the company has no revenue and is still losing money. Do you see further upside for this stock ? Should I continue to hold ?
Thank you for your excellent service and helpful advice as always.
Thank you for your answer on Eidos Therapeutic on 21st, June. I own this stock and has gone up 30% + thanks to your positive comment ( at least the ceo has bought 28m in shares), I usually hold on to my winner and let it runs, but I do not understand why it gone up so fast within a short period of time with no news.
As stated in your answer, the company has no revenue and is still losing money. Do you see further upside for this stock ? Should I continue to hold ?
Thank you for your excellent service and helpful advice as always.
-
Eidos Therapeutics Inc. (EIDX $122.21)
- $122.21 Cap: $4.72B
- View EIDX Profile
- View Questions on EIDX
Q: Hi 5i Team,
Pls give your thought and outlook for Eidos Therapeutics.
Thank you for your excellent service as always.
Pls give your thought and outlook for Eidos Therapeutics.
Thank you for your excellent service as always.
Insiders
Share Information
SEC Filings
News and Media